Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/16520

Type
Article
Copyright
Restricted access
Embargo date
2030-01-01
Collections
Share

Statistics
Metadata
Show full item record

GLOBAL UPDATE ON THE SUSCEPTIBILITY OF HUMAN INFLUENZA VIRUSES TO NEURAMINIDASE INHIBITORS, 2014-2015
Hurt, Aeron C. et al. | Date Issued: 2016
Author
Hurt, Aeron C.
Besselaar, Terry G.
Daniels, Rod S.
Ermetal, Burcu
Fry, Alicia
Gubareva, Larisa
Huang, Weijuan
Lackenby, Angie
Lee, Raphael T. C.
Lo, Janice
Maurer-Stroh, Sebastian
Nguyen, Ha T.
Pereyaslov, Dmitriy
Rebelo-de-Andrade, Helena
Siqueira, Marilda Agudo Mendonça Teixeira de
Takashita, Emi
Tashiro, Masato
Tilmanis, Danielle
Wang, Dayan
Zhang, Wenqing
Meijer, Adam
Affilliation
Peter Doherty Institute for Infection and Immunity. WHO Collaborating Centre for Reference and Research on Influenza, VIDRL. Melbourne, Victoria, Australia / University of Melbourne. Melbourne School of Population and Global Health. Parkville, Victoria, Australia.
World Health Organization, Global Influenza Programme. Geneva, Switzerland.
The Francis Crick Institute. Worldwide Influenza Centre (WIC). Mill Hill Laboratory (formerly the WHO CC for Reference and Research on Influenza, MRC, National Institute for Medical Research). The Ridgeway, London, UK.
The Francis Crick Institute. Worldwide Influenza Centre (WIC). Mill Hill Laboratory (formerly the WHO CC for Reference and Research on Influenza, MRC, National Institute for Medical Research). The Ridgeway, London, UK.
WHO Collaborating Center for the Surveillance, Epidemiology and Control of Influenza, Centers for Diseases Control and Prevention. Atlanta, GA, USA.
WHO Collaborating Center for the Surveillance, Epidemiology and Control of Influenza, Centers for Diseases Control and Prevention. Atlanta, GA, USA.
WHO Collaborating Centre for Reference and Research on Influenza. National Institute for Viral Disease Control and Prevention. Collaboration Innovation Center for Diagnosis and Treatment of Infectious Diseases. China CDC, Beijing, China.
Public Health England. National Infection Service. London, UK.
Bioinformatics Institute. Agency for Science, Technology and Research. Matrix, Singapore.
Public Health Laboratory Centre. 382 Nam Cheong Street, Hong Kong, China.
Bioinformatics Institute. Agency for Science, Technology and Research. Matrix, Singapore / Nanyang Technological University. School of Biological Sciences. Singapore / Ministry of Health. National Public Health Laboratory. Singapore, Singapore.
WHO Collaborating Center for the Surveillance, Epidemiology and Control of Influenza, Centers for Diseases Control and Prevention. Atlanta, GA, USA.
World Health Organization Regional Office for Europe. Division of Communicable Diseases, Health Security, & Environment. Copenhagen, Denmark.
Instituto Nacional de Saúde, Lisboa, Portugal / Universidade de Lisboa. Faculdade de Farmácia. Lisboa, POrtugal.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Vírus Respiratórios. Rio de Janeiro, RJ, Brasil.
WHO Collaborating Centre for Reference and Research on Influenza. National Institute of Infectious Diseases. Tokyo, Japan.
WHO Collaborating Centre for Reference and Research on Influenza. National Institute of Infectious Diseases. Tokyo, Japan.
Peter Doherty Institute for Infection and Immunity. WHO Collaborating Centre for Reference and Research on Influenza, VIDRL. Melbourne, Victoria, Australia.
WHO Collaborating Centre for Reference and Research on Influenza. National Institute for Viral Disease Control and Prevention. Collaboration Innovation Center for Diagnosis and Treatment of Infectious Diseases. China CDC, Beijing, China.
World Health Organization, Global Influenza Programme. Geneva, Switzerland.
National Institute for Public Health and the Environment. Bilthoven, Netherlands.
Abstract
The World Health Organization (WHO) Collaborating Centres for Reference and Research on Influenza (WHO CCs) tested 13,312 viruses collected by WHO recognized National Influenza Centres between May 2014 and May 2015 to determine 50% inhibitory concentration (IC50) data for neuraminidase inhibitors (NAIs) oseltamivir, zanamivir, peramivir and laninamivir. Ninety-four per cent of the viruses tested by the WHO CCs were from three WHO regions: Western Pacific, the Americas and Europe. Approximately 0.5% (n = 68) of viruses showed either highly reduced inhibition (HRI) or reduced inhibition (RI) (n = 56) against at least one of the four NAIs. Of the twelve viruses with HRI, six were A(H1N1)pdm09 viruses, three were A(H3N2) viruses and three were B/Yamagata-lineage viruses. The overall frequency of viruses with RI or HRI by the NAIs was lower than that observed in 2013-14 (1.9%), but similar to the 2012-13 period (0.6%). Based on the current analysis, the NAIs remain an appropriate choice for the treatment and prophylaxis of influenza virus infections.
Keywords in Portuguese
Vírus da gripe
Resistência antiviral
Inibidores da neuraminidase
Oseltamivir
Análise global
Redução da suscetibilidade
 
Keywords
Influenza virus
Antiviral resistance
Neuraminidase inhibitors
Oseltamivir
Global analysis
Reduced susceptibility
 
Publisher
Elsevier Masson
Citation
HURT, Aeron C. et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014 e 2015. Antiviral Research, v.132, p.178-185, June 2016.
DOI
10.1016/j.antiviral.2016.06.001
ISSN
0166-3542